50 results on '"Rönnelid, Johan"'
Search Results
2. Correspondence on ‘Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities’
3. Response to: ‘Comment on: standardisation of myositis-specific antibodies: where are we today?’ by Infantino et al
4. A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation
5. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study
6. Response to: ‘Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?’ by Cavazzana et al
7. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies
8. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
9. Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?
10. Response to: ‘Detection of myositis-specific antibodies: additional notes’ by Infantino et al
11. Response to: ‘Detection of myositis-specific antibodies’ by Vulstekeet al
12. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants
13. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
14. Antibodies against collagen type II are not a general marker of acute arthritis onset
15. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up
16. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation
17. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus
18. The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies against uncitrullinated peptides seem to occur prior to the antibodies to the corresponding citrullinated peptides
19. A1.11 Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in ra patients with anti-collagen antibodies
20. A1.1 Characterisation of lung inflammation and identification of shared citrullinated targets in the lungs and joints of early rheumatoid arthritis
21. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
22. Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis
23. A5.24 Neutrophil Granulocytes Respond to Surface-Bound Immune Complexes Containing Anti-Type II Collagen Antibodies from RA Patients
24. A10.15 IgA Rheumatoid Factor is more Predominant than anti-CCP in Sudanese Rheumatoid Arthritis Patients, whereas IgG RF is a Strong Prognostic Marker and Associated with Early Onset
25. A6.10 High Disease Activity and Erosion Rate in Sudanese Rheumatoid Arthritis Patients
26. A5.12 Disappearance and Reappearance of IgG, IgA and IgM Autoantibody Isotypes and Immune Complexes in Rituximab-Treated SLE Patients
27. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
28. Antibodies against native collagen and citrullinated proteins precede the development of rheumatoid arthritis with a consecutive pattern
29. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden
30. Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis
31. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis
32. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
33. Correspondence on 'Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities'.
34. Response to: 'Comment on: standardisation of myositis-specific antibodies: where are we today?' by Infantino et al .
35. Response to: 'Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?' by Cavazzana et al .
36. Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?
37. Response to: 'Detection of myositis-specific antibodies: additional notes' by Infantino et al .
38. Response to: 'Detection of myositis-specific antibodies' by Vulsteke et al .
39. Antibodies against collagen type II are not a general marker of acute arthritis onset.
40. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants.
41. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.
42. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.
43. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus.
44. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.
45. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden.
46. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke.
47. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.
48. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis.
49. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis.
50. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.